Ladage Dennis, Rösgen Delia, Schreiner Clemens, Ladage Dorothee, Adler Christoph, Harzer Oliver, Braun Ralf J
Department of Internal Medicine, Danube Private University, Krems an der Donau, Austria.
Heart Center, University of Cologne, Cologne, Germany.
Front Med (Lausanne). 2021 Jun 17;8:653630. doi: 10.3389/fmed.2021.653630. eCollection 2021.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic recently. The prevalence and persistence of antibodies following a peak SARS-CoV-2 infection provides insights into the potential for some level of population immunity. In June 2020, we succeeded in testing almost half of the population of an Austrian town with a higher incidence of COVID-19 infection. We performed a follow-up study to reassess the prevalence of SARS-CoV-2-specific IgA and IgG antibodies with 68 participants of the previous study. We found that the prevalence of IgG or IgA antibodies remained remarkably stable, with 84% of our cohort prevailing SARS-CoV-2-specific antibodies (only a slight decrease from 93% 4 months before). In most patients with confirmed COVID-19 seroconversion potentially provides immunity to reinfection. Our results suggest a stable antibody response observed for at least 6 months post-infection with implications for developing strategies for testing and protecting the population.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）最近引发了一场全球大流行。SARS-CoV-2感染高峰后抗体的流行率和持续存在情况为一定程度的群体免疫潜力提供了见解。2020年6月，我们成功对奥地利一个新冠病毒感染发病率较高的城镇近一半人口进行了检测。我们对之前研究的68名参与者进行了一项随访研究，以重新评估SARS-CoV-2特异性IgA和IgG抗体的流行率。我们发现，IgG或IgA抗体的流行率保持显著稳定，我们队列中有84%的人存在SARS-CoV-2特异性抗体（仅比4个月前的93%略有下降）。在大多数确诊感染新冠病毒的患者中，血清转化可能提供对再次感染的免疫力。我们的结果表明，感染后至少6个月观察到抗体反应稳定，这对制定检测和保护人群的策略具有启示意义。
